Danaher Additional Paid-in Capital 2010-2025 | DHR
Danaher additional paid-in capital from 2010 to 2025. Additional paid-in capital can be defined as the excess over par value paid for common securities.
- Danaher additional paid-in capital for the quarter ending March 31, 2025 was $16.845B, a 18.5% increase year-over-year.
- Danaher additional paid-in capital for 2024 was $16.727B, a 3.44% increase from 2023.
- Danaher additional paid-in capital for 2023 was $16.17B, a 33.95% increase from 2022.
- Danaher additional paid-in capital for 2022 was $12.072B, a 19.64% increase from 2021.
| Danaher Annual Additional Paid-in Capital (Millions of US $) |
|
|---|---|
| 2024 | $16,727 |
| 2023 | $16,170 |
| 2022 | $12,072 |
| 2021 | $10,090 |
| 2020 | $9,698 |
| 2019 | $7,565 |
| 2018 | $5,834 |
| 2017 | $5,538 |
| 2016 | $5,313 |
| 2015 | $4,981 |
| 2014 | $4,481 |
| 2013 | $4,158 |
| 2012 | $3,688 |
| 2011 | $3,877 |
| 2010 | $2,412 |
| 2009 | $2,075 |
| Danaher Quarterly Additional Paid-in Capital (Millions of US $) |
|
|---|---|
| 2025-03-31 | $16,845 |
| 2024-12-31 | $16,727 |
| 2024-09-30 | $9,304 |
| 2024-06-30 | $9,806 |
| 2024-03-31 | $14,215 |
| 2023-12-31 | $16,170 |
| 2023-09-30 | $14,085 |
| 2023-06-30 | $13,939 |
| 2023-03-31 | $12,130 |
| 2022-12-31 | $12,072 |
| 2022-09-30 | $11,985 |
| 2022-06-30 | $11,854 |
| 2022-03-31 | $10,123 |
| 2021-12-31 | $10,090 |
| 2021-09-30 | $10,004 |
| 2021-06-30 | $9,890 |
| 2021-03-31 | $9,794 |
| 2020-12-31 | $9,698 |
| 2020-09-30 | $9,618 |
| 2020-06-30 | $9,475 |
| 2020-03-31 | $7,630 |
| 2019-12-31 | $7,565 |
| 2019-09-30 | $7,502 |
| 2019-06-30 | $7,483 |
| 2019-03-31 | $7,376 |
| 2018-12-31 | $5,834 |
| 2018-09-30 | $5,772 |
| 2018-06-30 | $5,706 |
| 2018-03-31 | $5,611 |
| 2017-12-31 | $5,538 |
| 2017-09-30 | $5,472 |
| 2017-06-30 | $5,424 |
| 2017-03-31 | $5,371 |
| 2016-12-31 | $5,313 |
| 2016-09-30 | $5,263 |
| 2016-06-30 | $5,221 |
| 2016-03-31 | $5,073 |
| 2015-12-31 | $4,981 |
| 2015-09-30 | $4,887 |
| 2015-06-30 | $4,728 |
| 2015-03-31 | $4,624 |
| 2014-12-31 | $4,481 |
| 2014-09-30 | $4,381 |
| 2014-06-30 | $4,285 |
| 2014-03-31 | $4,220 |
| 2013-12-31 | $4,158 |
| 2013-09-30 | $4,089 |
| 2013-06-30 | $4,013 |
| 2013-03-31 | $3,887 |
| 2012-12-31 | $3,688 |
| 2012-09-30 | $3,962 |
| 2012-06-30 | $4,134 |
| 2012-03-31 | $4,016 |
| 2011-12-31 | $3,877 |
| 2011-09-30 | $3,801 |
| 2011-06-30 | $3,747 |
| 2011-03-31 | $2,683 |
| 2010-12-31 | $2,412 |
| 2010-09-30 | $2,308 |
| 2010-06-30 | $2,257 |
| 2010-03-31 | $2,125 |
| 2009-12-31 | $2,075 |
| 2009-09-30 | $1,976 |
| 2009-06-30 | $1,905 |
| 2009-03-31 | $1,854 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $136.657B | $23.875B |
| Danaher Corporation is a global conglomerate that designs, manufactures and markets diverse lines of professional, industrial, commercial and consumer products. The company's segmental details are provided below: Life Sciences segment offers a broad range of research tools used to analyze a range of critical areas including genes, proteins, metabolites and cells to understand the causes of diseases, identify new therapies, and test new drugs and vaccines. Range of industries served includes biopharmaceutical, food and beverage, medical, aerospace, microelectronics, and general industrial. Diagnostics segment offers analytical instruments, reagents, consumables, software and services that are deployed in reference laboratories, hospitals, physicians' offices and other critical care settings. It helps to diagnose diseases and take suitable treatment decisions. Environmental & Applied Solutions segment offers products and services that help keep food and water supplies safe globally. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Elevance Health (ELV) | United States | $88.114B | 11.37 |
| CVS Health (CVS) | United States | $76.496B | 9.51 |
| Cencora (COR) | United States | $55.428B | 19.28 |
| DiDi Global (DIDIY) | China | $22.215B | 33.71 |
| Natera (NTRA) | United States | $20.400B | 0.00 |
| BioMerieux (BMXMF) | France | $15.355B | 0.00 |
| Solventum (SOLV) | United States | $12.620B | 13.36 |
| EUROFINS SCIENT (ERFSF) | Luxembourg | $12.158B | 0.00 |
| CochLear (CHEOY) | Australia | $11.298B | 0.00 |
| Doximity (DOCS) | United States | $10.912B | 50.83 |
| Revvity (RVTY) | United States | $10.655B | 18.34 |
| ICON (ICLR) | Ireland | $10.552B | 9.81 |
| Viatris (VTRS) | United States | $10.317B | 3.54 |
| Avantor (AVTR) | United States | $8.750B | 12.71 |
| Medpace Holdings (MEDP) | United States | $8.519B | 22.63 |
| HealthEquity (HQY) | United States | $8.446B | 41.55 |
| Sonic Healthcare (SKHHY) | Australia | $8.201B | 0.00 |
| Charles River Laboratories (CRL) | United States | $6.822B | 13.37 |
| Amplifon S.p.A (AMFPF) | Italy | $4.966B | 26.21 |
| BrightSpring Health Services (BTSG) | United States | $4.185B | 38.74 |
| Bausch + Lomb (BLCO) | Canada | $4.171B | 24.58 |
| Sotera Health (SHC) | United States | $3.616B | 20.55 |
| Surgery Partners (SGRY) | United States | $3.029B | 39.39 |
| Alignment Healthcare (ALHC) | United States | $2.948B | 0.00 |
| Concentras Parent (CON) | United States | $2.925B | 16.90 |
| Organon (OGN) | United States | $2.280B | 2.42 |
| Ardent Health Partners (ARDT) | United States | $2.179B | 9.29 |
| Progyny (PGNY) | United States | $1.882B | 41.42 |
| Premier (PINC) | United States | $1.877B | 14.24 |
| GeneDx Holdings (WGS) | United States | $1.815B | 69.90 |
| PACS (PACS) | United States | $1.625B | 0.00 |
| GoodRx Holdings (GDRX) | United States | $1.432B | 28.64 |
| Pediatrix Medical (MD) | United States | $1.278B | 9.73 |
| Teladoc Health (TDOC) | United States | $1.272B | 0.00 |
| Establishment Labs Holdings (ESTA) | $1.059B | 0.00 | |
| Agilon Health (AGL) | United States | $1.056B | 0.00 |
| Ryman Healthcare (RYHTY) | New Zealand | $0.998B | 0.00 |
| Nutex Health (NUTX) | United States | $0.967B | 14.61 |
| CareDx (CDNA) | United States | $0.896B | 14.00 |
| AMN Healthcare Services Inc (AMN) | United States | $0.857B | 8.02 |
| QDM (QDMI) | Hong Kong, SAR China | $0.729B | 0.00 |
| Embecta (EMBC) | United States | $0.681B | 4.59 |
| InnovAge Holding (INNV) | United States | $0.570B | 0.00 |
| Enhabit (EHAB) | United States | $0.545B | 44.83 |
| Auna S.A (AUNA) | Luxembourg | $0.514B | 13.63 |
| Sonida Senior Living (SNDA) | United States | $0.493B | 0.00 |
| LifeMD (LFMD) | United States | $0.439B | 0.00 |
| COMPASS Pathways (CMPS) | United Kingdom | $0.367B | 0.00 |
| SBC Medicals (SBC) | United States | $0.361B | 0.00 |
| Oncology Institute (TOI) | United States | $0.230B | 0.00 |
| Beauty Health (SKIN) | United States | $0.217B | 0.00 |
| Performant Healthcare (PHLT) | United States | $0.204B | 0.00 |
| DocGo (DCGO) | United States | $0.143B | 23.33 |
| Sera Prognostics (SERA) | United States | $0.090B | 0.00 |
| KindlyMD (KDLY) | United States | $0.083B | 0.00 |
| So-Young (SY) | China | $0.083B | 0.00 |
| OncoCyte (OCX) | United States | $0.080B | 0.00 |
| Ascend Wellness Holdings (AAWH) | United States | $0.071B | 0.00 |
| NeueHealth (NEUE) | United States | $0.062B | 0.00 |
| IceCure Medical (ICCM) | Israel | $0.057B | 0.00 |
| Basel Medical Group (BMGL) | Singapore | $0.049B | 0.00 |
| Pheton Holdings (PTHL) | China | $0.035B | 0.00 |
| NeuroOne Medical Technologies (NMTC) | United States | $0.033B | 0.00 |
| Biodesix (BDSX) | United States | $0.032B | 0.00 |
| SeaStar Medical Holding (ICU) | United States | $0.013B | 0.00 |
| ModivCare (MODV) | United States | $0.013B | 0.00 |
| Co-Diagnostics (CODX) | United States | $0.010B | 0.00 |
| Intelligent Bio Solutions (INBS) | United States | $0.009B | 0.00 |
| BioNexus Gene Lab (BGLC) | $0.005B | 0.00 | |
| XWELL (XWEL) | United States | $0.005B | 0.00 |
| Aclarion (ACON) | United States | $0.004B | 0.00 |
| ISpecimen (ISPC) | United States | $0.003B | 0.00 |
| INVO Fertility (IVF) | United States | $0.002B | 0.00 |
| NewGenIvf Group (NIVF) | Thailand | $0.002B | 0.00 |
| Cano Health (CANOQ) | United States | $0.000B | 0.00 |